MedWatch

He bites his tongue for no one

A profile to remember: CEO of and partner in NB Capital, Florian Schönharting, spoke to MedWatch about, not just the all-time high return of his investment fund, but also a politically controversial suggestion to let those medical patients that can afford it, pay for the best medicine available. He simply has to comment on misconceptions, he points out.

There must be very few pharmaceuticals on the market that 43-year-old Florian Schönharting does not have knowledge of. For more than 20 years he has been working with investments in the pharmaceutical world, first as Asset Manager in BankInvest Asset Management and later on as founder of and partner in Nordic Biotech, now known as NB Capital, which means that he has seen several conjuncture-turns, made his mistakes – and learned from them.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Ambu peger på rettidig omhu som baggrund for MDR-milepæl

Ambu har fået alle sine produkter godkendt efter de nye EU-regler for medicinsk udstyr trods flaskehalse og ventetid, og det skyldes ifølge medicoselskabet, at virksomheden allerede på et tidligt tidspunkt anerkendte, hvor stor en indsats det ville kræve.

Her er de vigtigste nyheder fra MedWatch i uge 49

Novo Nordisk Fonden giver millioner til udvikling af RNA-vacciner, Danske Regioner vil investere "massivt" i sundhedsteknologi og Ellab får smæk på 5 mio. kr. i amerikansk told-opgør. Fik du det hele med?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier